RAD51B and Familial prostate cancer: Our data with RAD51B are consistent with published literature (33) and our results with ATM are in agreement with the differential responses observed in patients with prostate cancer harboring tumors with mutations in ATM treated with olaparib when compared with those carrying BRCA2 mutations (7).